Peer-reviewedCC BY-NCAlzheimer's & dementia (Amsterdam, Netherlands)
Blood TRPC6 mRNA as a biomarker for Alzheimer's disease: a nationwide, multicenter study in China.
11 affiliations
- 1National Clinical Research Center for Aging and Medicine, Huashan Hospital, State Key Laboratory of Medical Neurobiology Fudan University Shanghai China.
- 2Institute for Translational Brain Research, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science Fudan University Shanghai China.
- 3Institute of Neurology Huashan Hospital Fudan University Shanghai China.
- 4Department of Nuclear Medicine & PET Center Huashan Hospital, Fudan University Shanghai China.
- 5Department of Neurology Zhongshan Hospital, Fudan University Shanghai China.
- 6Department of Neurology and Institute of Neurology Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital Shanghai China.
- 7Shanghai Mental Health Center Shanghai Jiao Tong University School of Medicine Shanghai China.
- 8Department of Neurology Beijing Tiantan Hospital, Capital Medical University Beijing China.
- 9Department of Neurology The First Affiliated Hospital of USTC, University of Science and Technology of China Hefei China.
- 10The State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, and the Institutes of Brain Science Fudan University Shanghai China.
- 11Department of Clinical Laboratory Beijing Tiantan Hospital Capital Medical University Beijing China.
Abstract
Accessible blood-based biomarkers remain needed for Alzheimer's disease (AD) screening and diagnosis. We investigated whether blood transient receptor potential canonical 6 (TRPC6) could serve as a potential biomarker for AD. We enrolled 1254 individuals, including 366 patients with AD, 735 cognitively unimpaired (CU) individuals, and 153 individuals with non-AD neurological disorders. All patients with AD were confirmed to be amyloid beta positive (Aβ+) by Aβ positron emission tomography (PET). Blood TRPC6 messenger RNA (mRNA) levels were measured in all participants. In a subset, Aβ PET imaging and plasma biomarker assessments were performed. Blood TRPC6 mRNA levels differed significantly among the CU, AD, and non-AD groups, with the lowest levels observed in patients with AD. TRPC6 mRNA levels were associated with regional Aβ deposition and showed diagnostic performance comparable to several established plasma biomarkers, although slightly inferior to phosphorylated tau 217. Blood TRPC6 mRNA is markedly reduced in AD and may represent an accessible and clinically relevant blood biomarker for AD.
Related
- Real‐world clinical, biomarker, and imaging outcomes of lecanemab in Alzheimer's disease: a multicenter longitudinal cohort study in Jiangsu, China
- Blood–CSF MiRNA Signatures in Alzheimer’s Disease Reveal Novel Biomarker Candidates: A Systematic Review
- Multi-Scale MRI, Radiology Reports, and Blood Biomarker–Guided Multimodal Deep Learning for Predicting Postoperative Recurrence in Cervical Cancer: A Multicenter Study
- Single-cell, spatial, and machine learning analyses identify ANKIB1 as an oligodendrocyte-anchored palmitoylation-associated candidate biomarker of Alzheimer’s disease
- Olfactory neuroepithelium biomarker platform: a proof from Alzheimer's disease
BibTeX
@article{pu2026blood,
title = {{Blood TRPC6 mRNA as a biomarker for Alzheimer's disease: a nationwide, multicenter study in China.}},
author = {Mei Pu and Yutong Wen and Yujing Chen and Jing Wang and Xiaoli Pan and Gang Wang and Xia Li and Guihong Wang and Chuantao Zuo and Jiong Shi and Liliang Zhu and Jie Wu and Rujing Ren and Xiaoqin Cheng and Shaowei Zhang and Jintao Wang and Shujing Liu and Ling Li and Fei Huang and Ding Ding and Yihui Guan and Chunjiu Zhong and Qianhua Zhao and Yizheng Wang},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2026},
month = oct,
doi = {10.1002/dad2.70433},
url = {https://europepmc.org/article/MED/42996798},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Blood TRPC6 mRNA as a biomarker for Alzheimer's disease: a nationwide, multicenter study in China.
AU - Mei Pu
AU - Yutong Wen
AU - Yujing Chen
AU - Jing Wang
AU - Xiaoli Pan
AU - Gang Wang
AU - Xia Li
AU - Guihong Wang
AU - Chuantao Zuo
AU - Jiong Shi
AU - Liliang Zhu
AU - Jie Wu
AU - Rujing Ren
AU - Xiaoqin Cheng
AU - Shaowei Zhang
AU - Jintao Wang
AU - Shujing Liu
AU - Ling Li
AU - Fei Huang
AU - Ding Ding
AU - Yihui Guan
AU - Chunjiu Zhong
AU - Qianhua Zhao
AU - Yizheng Wang
PY - 2026
DA - 2026/10/01
JO - Alzheimer's & dementia (Amsterdam, Netherlands)
DO - 10.1002/dad2.70433
UR - https://europepmc.org/article/MED/42996798
AB - Accessible blood-based biomarkers remain needed for Alzheimer's disease (AD) screening and diagnosis. We investigated whether blood transient receptor potential canonical 6 (TRPC6) could serve as a potential biomarker for AD. We enrolled 1254 individuals, including 366 patients with AD, 735 cognitively unimpaired (CU) individuals, and 153 individuals with non-AD neurological disorders. All patients with AD were confirmed to be amyloid beta positive (Aβ+) by Aβ positron emission tomography (PET). Blood TRPC6 messenger RNA (mRNA) levels were measured in all participants. In a subset, Aβ PET imaging and plasma biomarker assessments were performed. Blood TRPC6 mRNA levels differed significantly among the CU, AD, and non-AD groups, with the lowest levels observed in patients with AD. TRPC6 mRNA levels were associated with regional Aβ deposition and showed diagnostic performance comparable to several established plasma biomarkers, although slightly inferior to phosphorylated tau 217. Blood TRPC6 mRNA is markedly reduced in AD and may represent an accessible and clinically relevant blood biomarker for AD.
SN - 2352-8729
ER -